Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ORGANIZATION
ORGANIZATION
- Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
- 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
- Top Officials of FPMAJ, JGA Disagree on Progress in Generic Drug Use at CSIMC Expert Subcommittee Meeting
November 30, 2012
- Pharmaceutical Makers to Reap Equal Benefits from Premium for New Drug Development in Long Run: FPMAJ Chief Naito
November 29, 2012
- IGPA Annual Conference to Adopt Kyoto Declaration including Int’l Harmonization on Generic Evaluation Criteria
November 28, 2012
- JMA to Call on PAFSC Committee to Review Once Again Switch-OTC of Epadel
November 27, 2012
- 27 JPMA Member Companies’ 1st Half Sales Up 2.1%
November 26, 2012
- JPMA to Compile “Code of Practice,” Eyeing Implementation from April
November 16, 2012
- JPMA Reprimands Mitsubishi Tanabe for GMP Violation by Benesis
November 16, 2012
- JSPE to Introduce Pharmacovigilance Specialist Certification System to Support RMPs
November 14, 2012
- Industry, Academia Launch Project to Raise Public Awareness of COPD
November 1, 2012
- Officials from MOPH of Thailand Receive Quality Control Training: JPMA’s Int’l Cooperation Activities
October 26, 2012
- 1st Graduates Under 6-Year Pharmacy Education System Push Up Percentage of Qualified Pharmacists among Applicants for This Year’s MR Exam: MREAC
October 24, 2012
- Nearly 1,200 Municipalities Cover Full Cost of HPV Vaccinations: Expert Organization Survey
October 23, 2012
- Former Benesis GMP Violation: Ueda Vows to “Root Out” Problems in JBPO
October 19, 2012
- JBPO Looks to Boost Japan’s Self-Sufficiency Ratio of Plasma Derivatives, Mulls Further Integration: Pres. Ueda
October 18, 2012
- Mr Kaiya of Kyokai Kenpo Optimistic About Reaching 30% Generic Drug Use Target
October 18, 2012
- Sino-Japanese Pharmaceutical Exchange Symposium to Be Postponed at Request of China: OPMA
October 15, 2012
- OPMA Temporarily Freezes JBPO’s Appointment as Its Board Member, FPMAJ’s Member of Board of Trustees
October 15, 2012
- Permanent New Drug Premium, Expanded R&D Tax Credits Needed to Encourage Innovation and Investment: FPMAJ Chairman Naito
October 12, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…